Gilead CAR-T Joins Billion-Dollar Club As Biktarvy Sales Cross $10bn Mark
Veklury Declines As COVID-19 Demand Eases
Yescarta surged ahead of competitors Kymriah and Breyanzi, helping Gilead’s oncology sales exceed $2bn, while the company reported the strongest sales in its HIV-dominated core business since 2015.
